相关实验视频
Updated: Jun 15, 2025
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.1K
慢性自发性疹患者的血管炎会影响对奥马利祖马布的反应吗?
Thomas B Casale1, Benjamin Trzaskoma2, Michael Holden2
1Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA.
The World Allergy Organization journal
|August 28, 2024
概括
奥马利祖马布有效治疗带有血管的慢性自发性疹 (CSU). 建议所有患者每4周服用300毫克的剂量,以获得最佳的疾病管理.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 临床药理学 临床药理学
背景情况:
- 慢性自发性疹 (CSU) 与同时发生的血管带来了管理挑战.
- 奥马利祖马布在CSU的疗效得到认可,但血管患者的反应动力学需要进一步评估.
- 评估临床上有意义的反应时间对于优化治疗策略至关重要.
研究的目的:
- 评估CSU患者对奥马利祖马布有临床意义的反应的时间,通过血管瘤的存在或不存在进行分层.
- 为了比较不同剂量的奥马利祖马布在患有和没有血管的患者中的疗效.
- 为CSU患有血管的患者提供基于证据的奥马利祖马布剂量建议.
主要方法:
- 从第3期ASTERIA I和II随机双盲研究中对数据进行后期分析.
- 患有CSU的患者根据在基线出现 (n=216) 或缺乏 (n=265) 血管的情况进行了分类.
- 使用卡普兰-梅尔方法分析了疹活动得分 (UAS7) 的最小重要差异 (MID) 的时间.
主要成果:
- 在患有和没有血管的患者中,300毫克的奥马利祖马布表现出与MID相似的中位时间.
- 对于150毫克的奥马利祖马布,MID的中位时间与没有血管炎的患者的300毫克剂量相当.
- 然而,在患有血管的患者中,150毫克奥马利祖马布的MID的中位时间更长,这表明了剂量依赖的反应.
结论:
- 在CSU患有血管的患者中,对奥马利祖马布的治疗反应是剂量依赖的.
- 建议所有CSU患者每4周服用300毫克的奥马利祖马布,并与当前的临床指导方针保持一致.
- 这种剂量策略确保了对患有蜂和血管的患者的最佳管理.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
254
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
254
02:06Allergic Reactions
27.3K
Overview
27.3K
01:27Allergic Drug Reactions
824
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
824
01:30Hypersensitivities
562
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
562
01:19Antiasthma Drugs: Leukotriene Modifiers
259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
259
00:42Cross-reactivity
31.0K
Overview
31.0K